Patient and Physician Advocacy with Ashley Sumrall, MD

Oncology Overdrive

In this episode, host Shikha Jain, MD, speaks with Ashley Sumrall, MD, about advocacy outside of their oncology practices and organizations, what lies ahead for the field of neuro-oncology and more. • Welcome to another exciting episode of Oncology Overdrive :58 • About Sumrall 1:16 • The interview 2:54 • How did you end up in the neuro-oncology space? 3:21 • As a neuro-oncologist, how do you stay up-to-date with neurology, oncology and medicine? 7:28 • Is there a difference in the way you interact with a neuro-oncologist versus a medical oncologist? 8:58 • What drove you to get into the advocacy space? 10:09 • Do you predominantly do advocacy work through ASCO, or do you do it through other avenues as well? 12:20 • If someone is interested in getting involved in becoming an advocate with ASCO, on the local level or on the national level, what is the best way for them to start that process? 15:24 • How do you talk to people in and outside of organizations about current situations facing health care? 19:40 • If people are interested in learning more about the AMA or getting involved with an organization like the AMA, how can they do so? 22:31 • What do you see coming down the pipeline that you think is going to transform the neuro-oncology space? 27:16 • If someone could only listen to the last minute of this episode, what would you want them to take away? 30:04 • How to contact Sumrall 32:13 • Thanks for listening 32:56 Ashley L. Sumrall, MD, is a neuro-oncologist practicing at Levine Cancer Institute in Charlotte, NC. We’d love to hear from you! Send your comments/questions to Dr. Jain at [e-mail]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Sumrall can be reached on X, formerly known as Twitter: @AshleySumrallMD. Disclosures: Jain reports no relevant financial disclosures. Sumrall reports receiving funding from Bristol-Myers Squibb, Exelixis, Kura Oncology, Novocure and Oncoceutics, and being a consultant for Abbvie, Athenex, Bayer, Exelixis and Novocure.